Erie's Public Schools and Zurn Elkay Water Solutions Announce Donation for Cleaner, Healthier, Safer Drinking Water
Donated Elkay filters are tested and certified to reduce lead, PFAS, microplastics and other harmful contaminants.
Donation is part of Zurn Elkay's yearlong celebration of the 125th anniversary of the company's founding in Erie, home to 160 associates and three manufacturing and R&D facilities.
ERIE, Pa., May 22, 2025--(BUSINESS WIRE)--Zurn Elkay Water Solutions Corporation (NYSE: ZWS) and Erie's Public Schools (EPS) today announced the donation of 50 Elkay filtered bottle filling stations, eight filter conversion kits and five years of Elkay filters for each of the donated units, ensuring consistent delivery of cleaner, healthier, safer drinking water to students, faculty, staff and community members.
In an event at EPS's JoAnna Connell Elementary School, 1820 E. 38th Street, Mayor Joseph V. Schember, incoming EPS Superintendent Natalyn Gibbs, EdD, and Zurn Elkay Chairman and CEO Todd A. Adams celebrated the donation with a class of first-grade students. This summer, the donated units will be installed across nine EPS elementary schools, replacing unfiltered drinking fountains with one filtered bottle filling station per 100 students; EPS has four Elkay filtered bottle filling stations already slated for installation at the new Edison Elementary School, set to open in Fall 2025. Additionally, all faucets in EPS's Culinary Center will be retrofitted to Elkay filtration, using donated conversion kits and filter cartridges.
"As an urban school district that serves roughly 10,000 students and their families, it is important that Erie's Public Schools is a leader in the charge to provide access to clean, lead-free water," Dr. Gibbs said. "We are so grateful to our partners at Zurn Elkay Water Solutions for their incredibly generous donation, which helps us deliver the kind of healthy school environments that students need to thrive."
Elkay filters are tested and certified to NSF/ANSI 42, 53 and 401 to reduce lead, PFAS (PFOA/PFOS), microplastics and other harmful contaminants. Since 2012, the use of Elkay bottle filling stations has eliminated the need for more than 103 billion single-use plastic bottles.
"For kids across the country, including right here in Erie, school buildings are more than just places for learning and social growth—they're also a vital source of drinking water," said Adams. "Elkay filtered bottle filling stations and drinking fountains are an immediate and cost-effective solution to expensive and laborious infrastructure upgrades. We are so proud of our Erie heritage and that is why we are making this donation to help ensure that students, teachers and staff members have access to cleaner, healthier, safer drinking water."
The donation is part of Zurn Elkay's yearlong celebration of the 125th anniversary of the company's founding in Erie. In 1900, the ambitious 26-year-old John A. Zurn purchased the patent and casts for a backwater valve from the local foundry and set up shop in his mother's barn in Erie. His entrepreneurial spirit, quest for growth and commitment to meeting—and exceeding—his customers' needs formed the foundation of today's Zurn Elkay Water Solutions. During the week of May 19-23, the company is commemorating the milestone with employee celebrations at its more than two dozen locations across the United States, including in Erie, where more than 160 associates are based.
"For 125 years Zurn Elkay's associates have contributed to Erie's enduring legacy as a city that balances its commitment to its people, the potential of its industry, and the preservation of its natural resources," Mayor Schember said, issuing a proclamation of May 22, 2025, as "Zurn Elkay Water Solutions Day" in the City of Erie. "We are fortunate to have such a successful business in Erie, and I wish Zurn Elkay many more years of continued success."
"John A. Zurn had the vision and the drive to prevent contamination of water sources… but he didn't do it alone," Adams added. "He had a family, friends, partners and a community to support him, and we're honored to have been part of that community for 125 years."
For photos and video from today's announcement, please visit
zurnelkay.com/press-room/press-kits.
About Erie's Public Schools
Erie's Public Schools consists of 16 schools that serve approximately 10,000 students each day. By actively engaging students in their learning through a high-quality, Common Core-aligned curriculum and excellent teaching, Erie's Public Schools is raising expectations and creating a culture of high expectations, collaboration, respect and accountability. Our primary objective is to prepare city students to establish and achieve their higher education and career goals. We invite you to explore www.eriesd.org to discover how the district is partnering with families and the community to improve students' lives.
About Zurn Elkay Water Solutions
Named one of America's Most Responsible Companies and one of America's Greenest Companies by Newsweek and one of the World's Best Companies for Sustainable Growth by TIME, Zurn Elkay Water Solutions is headquartered in Milwaukee, WI, and is a growth-oriented, pure-play water management business that designs, procures, manufactures and markets what we believe to be the broadest sustainable product portfolio of specification-driven water management solutions to improve health, hydration, human safety and the environment. The Zurn Elkay product portfolio includes professional grade water safety and control products, flow systems products, hygienic and environmental products and filtered drinking water products for public and private spaces. Learn more at www.zurnelkay.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250522129749/en/
Contacts
Erica Erwin, Coordinator - PR & Strategic CommunicationsErie's Public Schoolseerwin@eriesd.org / 814-874-6035
Angela Hersil, VP - Corporate CommunicationsZurn Elkay Water Solutionscorporate.communications@zurnelkay.com / 855-480-5050
Kyle Hannon, Director - CommunicationsCity of Eriekhannon@erie.pa.us / 814-870-1285
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
EQT Corporation's (NYSE:EQT) high institutional ownership speaks for itself as stock continues to impress, up 3.0% over last week
Explore EQT's Fair Values from the Community and select yours Key Insights Significantly high institutional ownership implies EQT's stock price is sensitive to their trading actions A total of 15 investors have a majority stake in the company with 50% ownership Insiders have sold recently AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. A look at the shareholders of EQT Corporation (NYSE:EQT) can tell us which group is most powerful. We can see that institutions own the lion's share in the company with 88% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company. And last week, institutional investors ended up benefitting the most after the company hit US$33b in market cap. The one-year return on investment is currently 67% and last week's gain would have been more than welcomed. Let's take a closer look to see what the different types of shareholders can tell us about EQT. See our latest analysis for EQT What Does The Institutional Ownership Tell Us About EQT? Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. We can see that EQT does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at EQT's earnings history below. Of course, the future is what really matters. Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. EQT is not owned by hedge funds. The Vanguard Group, Inc. is currently the largest shareholder, with 12% of shares outstanding. BlackRock, Inc. is the second largest shareholder owning 7.6% of common stock, and Wellington Management Group LLP holds about 6.9% of the company stock. After doing some more digging, we found that the top 15 have the combined ownership of 50% in the company, suggesting that no single shareholder has significant control over the company. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Quite a few analysts cover the stock, so you could look into forecast growth quite easily. Insider Ownership Of EQT The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions. Our most recent data indicates that insiders own less than 1% of EQT Corporation. It is a very large company, so it would be surprising to see insiders own a large proportion of the company. Though their holding amounts to less than 1%, we can see that board members collectively own US$229m worth of shares (at current prices). In this sort of situation, it can be more interesting to see if those insiders have been buying or selling. General Public Ownership The general public-- including retail investors -- own 11% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. Next Steps: While it is well worth considering the different groups that own a company, there are other factors that are even more important. I like to dive deeper into how a company has performed in the past. You can access this interactive graph of past earnings, revenue and cash flow, for free. If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
an hour ago
- Yahoo
1 Stock Down 40% This Year to Buy and Hold
Key Points Novo Nordisk's shares have been trending downward due to clinical setbacks and underwhelming results. However, the company has some potential catalysts on the way that could jolt its stock price. Novo Nordisk looks attractive given its lineup and pipeline, especially at current levels. 10 stocks we like better than Novo Nordisk › Novo Nordisk (NYSE: NVO) first earned U.S. approval for its now-famous weight management medicine Wegovy in June 2021. That marked the beginning of a strong run for the company on the stock market. However, the Denmark-based drugmaker has given up most of these gains over the past year; the stock is down by 40% since January alone. Despite its recent misfortunes, Novo Nordisk's shares could still deliver strong returns to patient investors. Here's why. The weight management opportunity Novo Nordisk primarily develops medicines for diabetes and, in recent years, weight management. Its stock has plunged over the past year because its financial results haven't been as impressive as the market had hoped. It also faced some clinical setbacks, while its biggest rival in its core markets, Eli Lilly, earned some important wins. However, there's more to the story. The market for anti-obesity medications could grow at an incredibly rapid rate. Some analysts estimate that it will be worth $150 billion by 2035, compared to $15 billion last year. Novo Nordisk still has one of the deepest pipelines in the industry. In fact, it's challenging to find a company other than Eli Lilly that has more promising products. Recently, Novo Nordisk expanded its pipeline through various licensing deals. Here's one more thing that recently broke its way: Eli Lilly's oral GLP-1 candidate, orforglipron, did not perform nearly as well as expected in a phase 3 study. This opens the door for Novo Nordisk to catch up to its longtime rival. The company's oral version of Wegovy is currently awaiting approval from regulators in the U.S. The oral version led to an average weight reduction of 13.6% in a phase 3 clinical trial, slightly higher than the 12.4% that orforglipron recently posted in its late-stage study. While it's always hard to compare across clinical trials, the data at the very least suggests that oral Wegovy is comparable to orforglipron -- but only the former drug is closing in on approval. Novo Nordisk also has yet another promising anti-obesity candidate in phase 3 studies, amycretin, which the Denmark-based pharmaceutical giant is testing in both subcutaneous and oral formulations. Why is the race to develop an oral weight loss option so important? Pills are easier and cheaper to manufacture, store, and transport. So, compared to injectable weight loss therapies, oral versions would allow drugmakers to produce them more cost-effectively and to expand the reach of weight loss therapies. On top of that, some patients are strongly averse to needles. Because the current leading weight management drugs are administered subcutaneously, an oral option would likely take a decent share of the market. Novo Nordisk is likely to be first to market. And the company could follow up that win with another oral product in amycretin. The price is right Let's go back to Novo Nordisk's recent and disappointing financial results. In the first half of the year, revenue rose by 16% year over year to 154.9 billion Danish kroner ($24.2 billion), while net profit came in at 55.5 billion DKK ($8.7 billion). Perhaps that's not quite what the market expected to see, but these are still excellent results for a pharmaceutical giant -- most drugmakers of that size would be happy to grow their revenue at high-single-digit or low-double-digit rates. Meanwhile, the stock appears reasonably valued, trading at 13 times forward earnings, compared to the healthcare industry's average of 16.2. What's the verdict? Novo Nordisk looks attractive at current levels, given the company's strong pipeline in weight management and a lineup that continues to deliver consistent profits. Despite recent setbacks, the stock is well-positioned to deliver excellent results over the long term. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 1 Stock Down 40% This Year to Buy and Hold was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Bath & Body Works, Inc. (NYSE:BBWI) Looks Like A Good Stock, And It's Going Ex-Dividend Soon
Explore Bath & Body Works's Fair Values from the Community and select yours Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Bath & Body Works, Inc. (NYSE:BBWI) is about to trade ex-dividend in the next four days. Typically, the ex-dividend date is one business day before the record date, which is the date on which a company determines the shareholders eligible to receive a dividend. The ex-dividend date is an important date to be aware of as any purchase of the stock made on or after this date might mean a late settlement that doesn't show on the record date. Therefore, if you purchase Bath & Body Works' shares on or after the 22nd of August, you won't be eligible to receive the dividend, when it is paid on the 5th of September. The company's next dividend payment will be US$0.20 per share, on the back of last year when the company paid a total of US$0.80 to shareholders. Based on the last year's worth of payments, Bath & Body Works has a trailing yield of 2.8% on the current stock price of US$28.68. Dividends are a major contributor to investment returns for long term holders, but only if the dividend continues to be paid. As a result, readers should always check whether Bath & Body Works has been able to grow its dividends, or if the dividend might be cut. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Dividends are usually paid out of company profits, so if a company pays out more than it earned then its dividend is usually at greater risk of being cut. Bath & Body Works has a low and conservative payout ratio of just 21% of its income after tax. That said, even highly profitable companies sometimes might not generate enough cash to pay the dividend, which is why we should always check if the dividend is covered by cash flow. It paid out 22% of its free cash flow as dividends last year, which is conservatively low. It's positive to see that Bath & Body Works's dividend is covered by both profits and cash flow, since this is generally a sign that the dividend is sustainable, and a lower payout ratio usually suggests a greater margin of safety before the dividend gets cut. View our latest analysis for Bath & Body Works Click here to see the company's payout ratio, plus analyst estimates of its future dividends. Have Earnings And Dividends Been Growing? Companies with consistently growing earnings per share generally make the best dividend stocks, as they usually find it easier to grow dividends per share. Investors love dividends, so if earnings fall and the dividend is reduced, expect a stock to be sold off heavily at the same time. Fortunately for readers, Bath & Body Works's earnings per share have been growing at 18% a year for the past five years. The company has managed to grow earnings at a rapid rate, while reinvesting most of the profits within the business. This will make it easier to fund future growth efforts and we think this is an attractive combination - plus the dividend can always be increased later. Another key way to measure a company's dividend prospects is by measuring its historical rate of dividend growth. Bath & Body Works has seen its dividend decline 5.2% per annum on average over the past 10 years, which is not great to see. It's unusual to see earnings per share increasing at the same time as dividends per share have been in decline. We'd hope it's because the company is reinvesting heavily in its business, but it could also suggest business is lumpy. Final Takeaway From a dividend perspective, should investors buy or avoid Bath & Body Works? Bath & Body Works has grown its earnings per share while simultaneously reinvesting in the business. Unfortunately it's cut the dividend at least once in the past 10 years, but the conservative payout ratio makes the current dividend look sustainable. Overall we think this is an attractive combination and worthy of further research. In light of that, while Bath & Body Works has an appealing dividend, it's worth knowing the risks involved with this stock. Every company has risks, and we've spotted 3 warning signs for Bath & Body Works (of which 1 shouldn't be ignored!) you should know about. A common investing mistake is buying the first interesting stock you see. Here you can find a full list of high-yield dividend stocks. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
